BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Glenamark Pharmaceuticals Ltd.'s Q2 revenues grew 4.9% YoY to Rs 2953 crore with 17.2% YoY growth in domestic sales to Rs 1051 crore due to additional contribution from Fabiflu (favipiravir) being partly offset by 11.3% decline in U.S. to Rs 752 crore.
Europe business grew 11.6% YoY to Rs 318 crore. Rest of World markets grew 9.1% YoY to 381 crore while the active pharmaceutical ingredient segment grew 19.1% YoY to Rs 321 crore.
Ebitda margins improved 272 basis points YoY to 18.7% mainly due to lower other expenditure.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
